Fosgonimeton shows potential as dementia treatment, Athira says
Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…